HelioLiver LDT now available to order through Quest Diagnostics
Two people holding hands in support
News & Media

October is Liver Cancer Awareness Month

Voices October 2023 5 min read By Justin Chen Li
Share

Helio Genomics CEO Justin Chen Li on why liver cancer — rising in frequency yet highly survivable when caught early — deserves the awareness spotlight this October.

Justin Chen Li, CEO of Helio Genomics
By Justin Chen Li
CEO, Helio Genomics

Featured in DOTmed HealthCare Business News. By Justin Chen Li, CEO of Helio Genomics.

When many people think of October, they think of breast cancer awareness – but that’s not the only pressing type of cancer we need to discuss at this time of year.

Annually, approximately 25,000 men and 11,000 women are diagnosed with liver cancer. We might not see football players dressed with ribbons to spread awareness, but it’s a dangerous form of cancer – and one that is rising in frequency.

Research shows that 90% of people with cancer survive if their disease is diagnosed at an early stage – and that is especially true with liver cancer. That’s why it is important to talk about liver cancer awareness. It’s crucial that people understand the signs, risk factors, and symptoms so that they can seek treatment as quickly as possible (and increase their chance of remission).

Read the full article at DOTmed HealthCare Business News.

Read the Full Article

This is an excerpt. Read the full byline article by Justin Chen Li on DOTmed HealthCare Business News.

Related Articles

More from Helio Genomics

NewsMay 12, 2026

HelioLiver Expands Access Through Quest

Helio broadens access to HelioLiver through Quest Diagnostics’ nationwide network of patient service centers.

Read more
NewsMay 8, 2026

Collaborating with the Rural Health Transformation Collaborative, Co-Chaired by Microsoft

Helio joins the Rural Health Transformation Collaborative, co-chaired by Microsoft, to expand rural early detection.

Read more
VoicesMay 6, 2026

Bharat Tewarie: Giving Patients a “Real Fighting Chance” Against Liver Cancer

Helio’s CEO reflects on the landmark CLiMB study and what earlier liver cancer detection means for patients.

Read more